Noxopharm Preclinical Data Further Supports Anti-Inflammatory Role of Idronoxil in the Treatment of COVID-19
Australian clinical-stage drug development company Noxopharm (ASX:NOX) has reported preclinical data that further supports the role of experimental anti-cancer drug, idronoxil, the active ingredient in Veyonda®, as an anti-inflammatory drug for early-stage COVID-19 treatments. A recent preclinical trial, conducted in partnership with Australia’s Hudson Institute of Medical Research (Hudson Institute), has identified that idronoxil inhibits the enzyme, TANK-binding kinase 1 (TBK1), an action that potentially dampens the inflammatory response causing the progression of COVID-19 disease from mild-to-severe, but not compromising the body’s ability to fight the virus.
These preclinical findings support preliminary top-line positive results the company shared earlier from its NOXCOVID Phase I clinical trial, which tested the suitability of idronoxil (Veyonda) as an effective anti-inflammatory in patients hospitalized with moderate COVID-19 disease. One particular relevance of TBK1 as a drug target is its role in responding to infections from RNA viruses including the respiratory RNA viruses - coronaviruses, influenza virus and respiratory syncytial virus.
Associate Professor Michael Gantier, Head of the Nucleic Acids and Innate Immunity Laboratory at Hudson Institute said: “TBK1 is a point of convergence of many inflammatory pathways, and a target under significant investigation by several big pharmaceutical companies. Our latest findings, which are being prepared for publication, demonstrate that idronoxil may have applications in a range of diseases where TBK1 facilitates aberrant inflammation. Critically, TBK1 also directly controls production of interferon-beta, a cytokine associated with long-COVID symptoms. This suggests that idronoxil may not only be useful to prevent progression of COVID-19 patients from mild to severe disease, but also may decrease the risk of long-lasting post-infectious symptoms, seen in up to half of COVID-19 patients.”
Noxopharm Limited (ASX:NOX) is an Australian clinical-stage drug development company focused on the treatment of cancer and cytokine storm (septic shock).
Veyonda® is the Company’s first pipe-line drug candidate currently in Phase 2 clinical trialling. Veyonda® has two main drug actions — a moderating effect on the ceramide/sphingosine-1-phosphate balance and inhibition of STING signalling. Activity against the former target contributes to its dual-acting oncotoxic and immunomodulatory functions designed to enhance the effectiveness and safety of standard oncology treatments, i.e., chemotherapies, radiation therapies, and immune checkpoint inhibitors. Activity against the latter target provides an anti-inflammatory effect, as well as contributing to an anti-cancer action, but also potentially blocking septic shock.
Noxopharm is running comprehensive drug discovery programs in both oncology and inflammation, and is the major shareholder of U.S. biotechnology company, Nyrada Inc (ASX:NYR), which is active in the areas of drug development for cardiovascular and neurological diseases.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Velodyne Lidar’s Intelligent Infrastructure Solution Selected for Major Deployment in University of California, Irvine Smart Cities Initiative28.9.2021 13:48:00 EEST | Press release
Velodyne Lidar, Inc. (Nasdaq: VLDR, VLDRW) today announced its Intelligent Infrastructure Solution has been selected by the HORIBA Institute for Mobility and Connectivity2 (HIMaC2) in the University of California, Irvine (UCI) Samueli School of Engineering. HIMaC2 plans to equip 25 intersections at UCI and the adjacent City of Irvine with Velodyne’s lidar-based Intelligent Infrastructure Solution as part of a major study on improving traffic and energy efficiency, road safety and air quality. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210928005328/en/ Velodyne Lidar announced its Intelligent Infrastructure Solution has been selected by the HORIBA Institute for Mobility and Connectivity² (HIMaC²) in the University of California, Irvine (UCI) Samueli School of Engineering. HIMaC² will use Velodyne’s lidar-based solution as part of a major study on improving traffic and energy efficiency, road safety and air quality. (Photo
Ibsen Scope Is Announcing Grants 202228.9.2021 13:00:00 EEST | Press release
Ibsen Scope Grants 2022 are now applicable for individual artists, theatre companies, institutions and organizations worldwide. The program amount to a total of NOK 2.000.000,-. (Approx. Euro 205.000,- /USD 248.000,-). The program offers funding for innovative performing arts projects. The projects must act as incentives for critical discourses on society related matters and be based on one or more of Henrik Ibsen’s plays. Applications are submitted through our website, and an appointed jury will evaluate the applications. For further information, statutes and application form see www.ibsenscope.com Deadline for applications is December 9th 2021. The winners of the Ibsen Scope Grants 2022 will be invited to Ibsen Scope Festival at Teater Ibsen in Skien, Norway in May 2022. Not heard of Ibsen Scope? We have changed our name. Ibsen Awards is now Ibsen Scope! We still look at the world through Henrik Ibsen’s lenses. We still engage in vivid, critical and artistic discourses on the works a
REPLY: Countdown to the Reply Cyber Security Challenge 202128.9.2021 10:30:00 EEST | Press release
On the 15th of October 2021, Reply will launch the fourth edition of the Reply Cyber Security Challenge, a team-based coding competition open to young professionals and cyber security enthusiasts from all over the world. This year’s edition will be supported by Intesa Sanpaolo, one of the top banking groups in Europe, and Immersive Labs, the platform empowering businesses to increase, measure and evidence human capability in every part of their cybersecurity. Intesa Sanpaolo‘s support confirms its commitment to increase education, awareness and training on cybersecurity among young people. Improving cybersecurity knowledge, skills and judgement is Immersive Labs’ mission and the Reply Cyber Security Challenge represents a new and engaging way to power up people’s cyber capabilities. The challenge, which in 2020 welcomed more than 10,000 participants from 160 countries gather together in 2,380 teams, aims to put teams (from 2 to 4 players) in competition in a 24-hour marathon, Capture T
Speech Processing Solutions (SPS) becomes a Nuance Dragon Medical One Distributor in Europe and Asia Pacific Region28.9.2021 10:02:00 EEST | Press release
Speech Processing Solutions (SPS), a leader in professional dictation, has announced they are joining forces with Nuance Communications as an official distributor of Nuance Dragon Medical One, the leading cloud-based speech recognition solution for clinical documentation, in Europe and Asia Pacific Regions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210928005069/en/ © Philips Dictation (Photo: Business Wire) One-stop shop for all voice-to-text needs This agreement enables SPS to become a one-stop-shop for healthcare solution partners and resellers providing dictation, speech recognition, and transcription software, as well as all hardware needs. The Nuance Dragon Medical One solution, which allows clinicians to document the complete patient record by voice, can now be easily combined with leading dictation workflow software and dictation hardware, such as the leading Philips SpeechMike line-up. Dr. Thomas Brauner, CEO of
Tigo Energy to Reveal New Solutions for Solar Fleet Management and Fire Safety at Intersolar Europe28.9.2021 10:00:00 EEST | Press release
Tigo Energy, Inc., the solar industry’s worldwide leader in Flex MLPE (Module Level Power Electronics), confirms the Company’s presence at the upcoming Intersolar Europe in Munich, Germany. Tigo representatives will showcase the entire family of Tigo TS4 Flex MLPE devices, including the recently introduced TS4-A-2F and the Tigo Energy Intelligence software platform. Together, these Tigo products make up the most cost-effective and advanced solution for rapid shutdown on large-scale solar projects. Tigo Energy has led solar innovation with its Tigo TS4 Flex MLPE by providing the freedom for customers to choose the features and components for their solar installations. Over the past 12 months, Tigo released key updates and innovations to its Flex MLPE product line to address the growing demand for high-power solar modules and energy projects that call for a diversified set of fire safety, monitoring, management, and power optimization features. “The Tigo TS4 is a fixture in the systems w
Galderma to Unveil Ground-breaking Data From Across Its Leading Dermatology Portfolio and Showcase Major Update for Sensitive Skincare Brand CETAPHIL® at the 2021 EADV Congress28.9.2021 09:30:00 EEST | Press release
Galderma’s presence at the 2021 European Academy of Dermatology and Venereology (EADV) virtual congress on September 29 – October 2 will reveal new data and showcase the company’s sophisticated portfolio and services across the spectrum of dermatology. The company’s redesigned virtual booth will have dedicated areas presenting Galderma’s innovations in Consumer Care and Prescription Medicine. Unveiling new data in Prescription Medicine The congress will see the unveiling of exciting new data from Galderma relating to rosacea, acne, actinic keratosis, atopic dermatitis and prurigo nodularis. Attendees will have the opportunity to ask questions to the faculties during live Q&A sessions. On Thursday, September 30, Professor Alison Layton^ will chair the symposium Personalizing Acne: Consensus of Experts to Optimize Acne Management. Together with her co-speakers, Professor Layton will provide practical solutions for longitudinal management of acne. On the same day, Professor Gil Yosipovitc
ThreatConnect Expands Into South Africa, Partnering With Leading MSSP28.9.2021 08:00:00 EEST | Press release
ThreatConnect, Inc.®, the leader in reducing complexity and enabling better decision-making in cybersecurity, announced that it has entered a strategic partnership with BUI, Microsoft’s largest Security and Consulting Partner in South Africa. BUI is an award-winning Microsoft Azure Expert MSP, a member of the Microsoft Intelligent Security Association, and a Gold Microsoft Partner delivering cloud and security solutions, as well as professional services, in SA and across the world. With Cyber Risk Quantification (CRQ), Threat Intelligence Platform (TIP) and Security Orchestration, Automation, and Response (SOAR) capabilities combined, ThreatConnect unifies the actions of the security team around the most critical tasks, supports their response with streamlined and automated workflows, and strengthens the entire security ecosystem through powerful technology integrations. With ThreatConnect’s comprehensive intelligence-driven SOAR, BUI (among other MSSPs) sees a plethora of immediate be
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom